BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 25211630)

  • 1. Epigenetic regulation of EFEMP1 in prostate cancer: biological relevance and clinical potential.
    Almeida M; Costa VL; Costa NR; Ramalho-Carvalho J; Baptista T; Ribeiro FR; Paulo P; Teixeira MR; Oliveira J; Lothe RA; Lind GE; Henrique R; Jerónimo C
    J Cell Mol Med; 2014 Nov; 18(11):2287-97. PubMed ID: 25211630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EFEMP1 as a novel DNA methylation marker for prostate cancer: array-based DNA methylation and expression profiling.
    Kim YJ; Yoon HY; Kim SK; Kim YW; Kim EJ; Kim IY; Kim WJ
    Clin Cancer Res; 2011 Jul; 17(13):4523-30. PubMed ID: 21571867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic regulation of MDR1 gene through post-translational histone modifications in prostate cancer.
    Henrique R; Oliveira AI; Costa VL; Baptista T; Martins AT; Morais A; Oliveira J; Jerónimo C
    BMC Genomics; 2013 Dec; 14():898. PubMed ID: 24344919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic inactivation of EFEMP1 is associated with tumor suppressive function in endometrial carcinoma.
    Yang T; Qiu H; Bao W; Li B; Lu C; Du G; Luo X; Wang L; Wan X
    PLoS One; 2013; 8(6):e67458. PubMed ID: 23840707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidermal Growth Factor-Containing Fibulin-Like Extracellular Matrix Protein 1 (EFEMP1) Acts as a Potential Diagnostic Biomarker for Prostate Cancer.
    Shen H; Zhang L; Zhou J; Chen Z; Yang G; Liao Y; Zhu M
    Med Sci Monit; 2017 Jan; 23():216-222. PubMed ID: 28085790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic disruption of miR-130a promotes prostate cancer by targeting SEC23B and DEPDC1.
    Ramalho-Carvalho J; Martins JB; Cekaite L; Sveen A; Torres-Ferreira J; Graça I; Costa-Pinheiro P; Eilertsen IA; Antunes L; Oliveira J; Lothe RA; Henrique R; Jerónimo C
    Cancer Lett; 2017 Jan; 385():150-159. PubMed ID: 27984115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decreased expression of angiogenesis antagonist EFEMP1 in sporadic breast cancer is caused by aberrant promoter methylation and points to an impact of EFEMP1 as molecular biomarker.
    Sadr-Nabavi A; Ramser J; Volkmann J; Naehrig J; Wiesmann F; Betz B; Hellebrand H; Engert S; Seitz S; Kreutzfeld R; Sasaki T; Arnold N; Schmutzler R; Kiechle M; Niederacher D; Harbeck N; Dahl E; Meindl A
    Int J Cancer; 2009 Apr; 124(7):1727-35. PubMed ID: 19115204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel tumor-suppressor gene epidermal growth factor-containing fibulin-like extracellular matrix protein 1 is epigenetically silenced and associated with invasion and metastasis in human gastric cancer.
    Zhu XJ; Liu J; Xu XY; Zhang CD; Dai DQ
    Mol Med Rep; 2014 Jun; 9(6):2283-92. PubMed ID: 24718752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIC1 modulates prostate cancer progression by epigenetic modification.
    Zheng J; Wang J; Sun X; Hao M; Ding T; Xiong D; Wang X; Zhu Y; Xiao G; Cheng G; Zhao M; Zhang J; Wang J
    Clin Cancer Res; 2013 Mar; 19(6):1400-10. PubMed ID: 23340301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SFRP1 repression in prostate cancer is triggered by two different epigenetic mechanisms.
    García-Tobilla P; Solórzano SR; Salido-Guadarrama I; González-Covarrubias V; Morales-Montor G; Díaz-Otañez CE; Rodríguez-Dorantes M
    Gene; 2016 Nov; 593(2):292-301. PubMed ID: 27570179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of new differentially methylated genes that have potential functional consequences in prostate cancer.
    Kim JW; Kim ST; Turner AR; Young T; Smith S; Liu W; Lindberg J; Egevad L; Gronberg H; Isaacs WB; Xu J
    PLoS One; 2012; 7(10):e48455. PubMed ID: 23119026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expansion of epigenetic alterations in EFEMP1 promoter predicts malignant formation in pancreatobiliary intraductal papillary mucinous neoplasms.
    Yoshida K; Nagasaka T; Umeda Y; Tanaka T; Kimura K; Taniguchi F; Fuji T; Shigeyasu K; Mori Y; Yanai H; Yagi T; Goel A; Fujiwara T
    J Cancer Res Clin Oncol; 2016 Jul; 142(7):1557-69. PubMed ID: 27095449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of novel DNA-methylated genes that correlate with human prostate cancer and high-grade prostatic intraepithelial neoplasia.
    Devaney JM; Wang S; Funda S; Long J; Taghipour DJ; Tbaishat R; Furbert-Harris P; Ittmann M; Kwabi-Addo B
    Prostate Cancer Prostatic Dis; 2013 Dec; 16(4):292-300. PubMed ID: 23896626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aberrant epigenetic modifications in the CTCF binding domain of the IGF2/H19 gene in prostate cancer compared with benign prostate hyperplasia.
    Paradowska A; Fenic I; Konrad L; Sturm K; Wagenlehner F; Weidner W; Steger K
    Int J Oncol; 2009 Jul; 35(1):87-96. PubMed ID: 19513555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 5: Epigenetic Regulation of PD-L1.
    Palicelli A; Croci S; Bisagni A; Zanetti E; De Biase D; Melli B; Sanguedolce F; Ragazzi M; Zanelli M; Chaux A; Cañete-Portillo S; Bonasoni MP; Soriano A; Ascani S; Zizzo M; Castro Ruiz C; De Leo A; Giordano G; Landriscina M; Carrieri G; Cormio L; Berney DM; Gandhi J; Nicoli D; Farnetti E; Santandrea G; Bonacini M
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequent 14-3-3 sigma promoter methylation in benign and malignant prostate lesions.
    Henrique R; Jerónimo C; Hoque MO; Carvalho AL; Oliveira J; Teixeira MR; Lopes C; Sidransky D
    DNA Cell Biol; 2005 Apr; 24(4):264-9. PubMed ID: 15812243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic modification-dependent androgen receptor occupancy facilitates the ectopic TSPY1 expression in prostate cancer cells.
    Leng X; Liu M; Tao D; Yang B; Zhang Y; He T; Xie S; Wang Z; Liu Y; Yang Y
    Cancer Sci; 2021 Feb; 112(2):691-702. PubMed ID: 33185915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MTSS1 hypermethylation is associated with prostate cancer progression.
    Chen J; Huang L; Zhu Q; Wang Z; Tang Z
    J Cell Physiol; 2020 Mar; 235(3):2687-2697. PubMed ID: 31541465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA Methylation-Mediated Downregulation of DEFB1 in Prostate Cancer Cells.
    Lee J; Han JH; Jang A; Kim JW; Hong SA; Myung SC
    PLoS One; 2016; 11(11):e0166664. PubMed ID: 27835705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNA-27a-5p regulation by promoter methylation and MYC signaling in prostate carcinogenesis.
    Barros-Silva D; Costa-Pinheiro P; Duarte H; Sousa EJ; Evangelista AF; Graça I; Carneiro I; Martins AT; Oliveira J; Carvalho AL; Marques MM; Henrique R; Jerónimo C
    Cell Death Dis; 2018 Feb; 9(2):167. PubMed ID: 29415999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.